Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-08-16
2009-08-25
Lukton, David (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S410000, C540S472000, C540S465000, C540S145000
Reexamination Certificate
active
07579338
ABSTRACT:
The radiation sensitization potential of a candidate compound can be screened by determine its ability to generate one or more reactive oxygen species under appropriate conditions. Compounds determined to have radiation sensitization potential are employed in methods for treating atheroma, tumors and other neoplastic tissue as well as other conditions that typically responsive to radiation sensitization.
REFERENCES:
patent: 5011472 (1991-04-01), Aebischer et al.
patent: 5244671 (1993-09-01), Vogel et al.
patent: 5457183 (1995-10-01), Sessler et al.
patent: 5599928 (1997-02-01), Hemmi et al.
patent: 5622946 (1997-04-01), Sessler et al.
patent: 5762909 (1998-06-01), Uzgiris et al.
patent: 5776925 (1998-07-01), Young et al.
patent: 5798491 (1998-08-01), Magda et al.
patent: 5801229 (1998-09-01), Sessler et al.
patent: 5807874 (1998-09-01), LaVoie et al.
patent: 6004953 (1999-12-01), Volpin et al.
patent: 6136841 (2000-10-01), Platzek et al.
patent: 7109188 (2006-09-01), Sessler et al.
patent: 2006/0178314 (2006-08-01), Sessler et al.
patent: 0786253 (1997-07-01), None
patent: WO-00-01414 (2000-01-01), None
Adams et al., Radiation Res. 67:9-20 (1976).
Buettner et al., “Catalytic Metals, Ascorbate and Free Radicals: Combinations to Avoid,” Radiation Res. 145:532-541 (1996).
Chen et al., “A New Mammalian DNA Topoisomerase I Poison Hoechst 33342: Cytoxicity and Drug Resistance in Human Cell Cultures,” Cancer Res. 53:1332-1337 (1993).
Grossweiner et al., “Singlet Oxygen Generation by Metallotexaphyrins,” Photochem. & Photobiol. 1999, 70(2):138-145.
Harker et al., Cancer Res. 43:4943-4950 (1983).
Isoda et al., Change in Ascorbate Radical Production in an Irradiated Experimental Tumor with Increased Tumor Size, J. Cancer Res. 56:5741-5744 (1996).
Kimoto et al., “Enhancement of Antitumor Activity of Ascorbate Against Ehrlich Ascites Tumor Cells by the Copper: Glycylglycylhistidine Complex,” Cancer Res. 43 (2):824-828 (1983).
Khuntia, D. and Mehta, M., “Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors,” Expert Rev. Anticancer Ther. 4(6): 981-989 (2004).
Lehninger, Biochemistry 2nded., Worth Publishers Inc., Ch. 18, pp. 503-504 (1975).
Lin et al., “The Cytotoxic Activity of Hemaloheme: Evidence for Two Different Mechanisms,” Anal. Biochem. 161:323-331 (1987).
Makhey et al., “Protoberberine Alkaloids and Related Compounds as Dual Inhibitors of Mammalian Topoisomerase I and II,” Med. Chem. Res. 5:1-12 (1994).
Mehta et al., “Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain Metastases,” J. of Clin. Oncol. 21(13):2529-2536 (2003).
Mehta, M. And Suh, J., “Novel radiosensitizers for tumors of the central nervous system,” Curr. Op. in Investigational Drugs, 2004, vol. 5(12): 1284-1291.
Miles et al., “Population Pharmacokinetics of Motexaftn Gadolinium in Adults With Brain Metastases or Glioblastoma Multiforme,” J. Clin. Pharmacol. 2005;45:299-312.
Mody, T. and Sessler, J., “Texaphyrins: a new approach to drug development,” J. Porphyrins Phthalocyanines 2001;5:134-142.
Mossman, J. Immunol. Methods 65:55-63 (1983).
Parise et al., “Sensitive high-performance liquid chromatographic assay for motexafin gadolinium and motexafinlutetium in human plasma,” J. of Chromatography B, 749 (2000) 145-152.
Riley, Free Radicals in Biology: Oxidative Stress and the Effects of Ionizing Radiation, Int. J. Radiat. Biol. 65(1):27-33(1994).
Rockwell et al., J. Natl. Cancer Inst. 49:735-749 (1972).
Sessler et al., “Pulse Radiolytic Studies of Metallotexaphyrins int he Presence of Oxygen: Relevance of the Equilibrium with Superoxide Anion to the Mechanism of Action of the Radiation Sensitizer Motexafin Gadolinium (Gd-Tex2+, Xcytrin),” J. Phys. Chem. B 2001, 105, 1452-1457.
Sessler et al., “One-Electron Reducation and Oxidation Studies of th Radiations Sensitizer Gadolinium (III) Texaphyrin (PCI-120) and Other Water Soluble Metallotexaphyrins,” J. Phys. Chem. A, 103:787-794 (1999).
Sessler et al., Texaphyrins: Synthesis and Applicaitons, Accounts of Chem. Res. 27:43-50(1994).
U.S. Appl. No. 60/304,197, filed Oct. 29, 1997, Magda.
Bram, S. et al., “Vitamin C preferential toxicity for malignant melanoma cells,” Nature 284:629-631 (1980).
Young et al., Investigative Radiology 29:330-338 (1994).
Hemmi Greg
Magda Darren
Mody Tarak
Sessler Jonathan L.
Lukton David
Pharmacyclics Inc.
Wilson Sonsini Goodrich & Rosati
LandOfFree
Methods and compositions for treating atheroma, tumors and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating atheroma, tumors and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating atheroma, tumors and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4094823